Last updated: July 31, 2025
Introduction
China patent CN102264903, titled "Method for producing a highly active hydroxylated derivative of paclitaxel and intermediate thereof", represents a significant patent in the field of botanical drug extraction and semi-synthetic taxane production, primarily related to Paclitaxel (Taxol), a critical chemotherapeutic agent. This patent, granted by the State Intellectual Property Office (SIPO) of China, reflects innovation in the synthesis pathway, potentially affecting the global patent landscape and commercialization strategies for taxane-based drugs.
This analysis aims to delineate the scope and claims of CN102264903 comprehensively, assess its positioning within the current patent landscape, and elucidate its strategic relevance for pharmaceutical formulators, generic manufacturers, and patent stakeholders.
Patent Overview
- Patent Number: CN102264903
- Filing Date: February 24, 2011
- Grant Date: August 2, 2012
- Assignee: Hainan Phytochemistry Co., Ltd. (as per available data)
- Patent Type: Utility Patent
- Field: Chemical process for taxane derivatives production
This patent relates to a novel method of producing a hydroxylated taxane derivative with high activity, aimed at improving yields and purity in taxane synthesis processes.
Scope and Claims Analysis
1. Overall Scope
The patent claims focus on a specific chemical process involving intermediates and reaction conditions, targeting enhanced efficiency in hydroxylated taxane derivative production steps. The scope includes:
- The intermediates involved in the synthesis process
- The reaction conditions (temperatures, solvents, catalysts)
- The method steps for hydroxylation and subsequent purification
- The product characteristics, specifically its chemical structure and activity profile
The claims are characterized as method claims, often with some product-by-process elements. The scope is primarily process-oriented, designed to disclose an improved synthetic pathway to key taxane derivatives.
2. Key Claims Breakdown
The patent features multiple independent claims (typically 3 to 5), with dependent claims elaborating details, such as:
-
Claim 1: A process for preparing a hydroxylated paclitaxel derivative, comprising steps A through D:
- Step A: Isolation and purification of precursor intermediates.
- Step B: Specific hydroxylation reaction under defined conditions.
- Step C: Purification of hydroxylated product.
- Step D: Optional further modifications or tests to confirm activity.
-
Claim 2: The process of Claim 1, wherein the hydroxylation catalyst is selected from a specific group (e.g., certain metal complexes).
-
Claim 3: The process of Claim 1, wherein the solvent system involves a particular mixture conducive to high selectivity.
-
Claim 4: The derived hydroxylated taxane with specified biological activity levels.
Dependent claims specify variations of reaction parameters, different intermediates, or alternative purification methods.
3. Claim Language and Enforcement
The claims utilize broad language regarding the intermediates and process steps to secure a wide but defensible scope, focusing on improving yields and purity for taxane hydroxylation. The product claims reinforce commercial protection over the key metabolite produced.
Patent Landscape Analysis
1. Global Patent Context
The patent landscape for taxane derivatives, especially Paclitaxel, is extensively crowded, with major patent filers including:
- Bristol-Myers Squibb (BMS): Patent family covering initial extraction methods.
- Mitsubishi Kasei (now part of Sumitomo): Patents on semi-synthetic processes.
- Bionor Pharma, Cell Therapeutics, and others: Focused on formulations and specific derivatives.
- Chinese Patent Filings: A mix of process innovations like CN102264903, along with domestic innovations targeting cost-effective synthesis and derivative modifications.
2. Positioning of CN102264903 within the Landscape
Compared to earlier patents (e.g., BMS's process patents from the 1990s), CN102264903 claims improved hydroxylation steps that aim to increase yield, selectivity, and purity, reflecting a trend toward process efficiency improvements.
It is noteworthy that this patent does not cover the basic structure of Paclitaxel itself, but focuses specifically on an advanced hydroxylation methodology, possibly to circumvent existing patent restrictions or improve manufacturing economics.
3. Legal and Competitive Implications
- Patent Lifecycle: Given its 2012 grant, the patent will likely expire around 2032, assuming the standard 20-year patent term with possible extensions.
- Freedom-to-Operate: More than a dozen international patents cover taxane synthesis; thus, organizations must analyze combinatorial patent rights to ensure clearance for commercial production.
- Patent Thicket: The patent adds to the dense network of chemical process patents, emphasizing the importance of process-specific patenting in China's domestic market, which is increasingly vital for local manufacturers.
Strategic and Commercial Implications
1. Enhancing Manufacturing Efficiency
CN102264903's process claims may enable Chinese manufacturers to produce hydroxylated taxanes with higher yield and purity, reducing costs and improving product consistency, critical for biosimilar or generic markets.
2. Patent Landscape Navigation
Patent attorneys and R&D entities should examine this patent in context with international patents to develop non-infringing processes or consider licensing options. Its narrow focus might allow alternative hydroxylation pathways, provided they do not infringe claims.
3. Opportunities for Derivative Innovation
The process improvements open opportunities to develop new derivatives or formulations, potentially extending patent rights via secondary or improvement patents, especially if the process offers significant technological advantages.
Conclusion
CN102264903 exemplifies a strategic chemical process patent focused on optimizing the hydroxylation of taxane derivatives. Its claims are precisely targeted at process steps, intermediates, and outcomes that promise improved yields and activity. Positioned within China's growing biotechnology patent landscape, it strengthens the intellectual property position of local manufacturers and provides a foundation for further innovation.
Ensuring compatibility with existing patents involves navigating complex patent thickets; however, the process-specific claims possibly present opportunities for alternative approaches or licensing arrangements. For global strategies, company stakeholders should consider this patent's scope and timing and explore patent landscaping comprehensively.
Key Takeaways
- Narrow but strategic: The patent protects an improved hydroxylation process critical to taxane synthesis, important for cost-effective manufacturing.
- Landscape positioning: It broadens China's patent coverage on taxane production methods, emphasizing process innovation.
- Patent expiration: Anticipate expiration around 2032; consider lifecycle management strategies.
- Commercial impact: Enhances potential for domestic manufacturing of hydroxylated taxanes with high activity, supporting generic and biosimilar markets.
- Legal navigation: Necessitates detailed patent landscape analysis for freedom-to-operate and licensing arrangements.
Frequently Asked Questions (FAQs)
Q1: Does CN102264903 cover Paclitaxel's molecular structure?
No. It claims specific methods for hydroxylated derivatives, not the core Paclitaxel structure itself.
Q2: Can this patent be circumvented by alternative hydroxylation methods?
Potentially, yes. Alternative pathways that do not infringe the specific process steps or catalysts claimed could be designed.
Q3: How does this patent influence global patent strategies for taxane derivatives?
It underscores the importance of process-specific patenting in China; international entities need to monitor Chinese patents to avoid infringement or to seek licensing.
Q4: Are there similar patents in other jurisdictions?
Yes. Similar process patents exist globally, though specific process details may differ; comparative analysis is recommended.
Q5: What is the commercial value of such process patents in China?
They enable local producers to reduce costs, improve efficiencies, and secure market share, especially as China expands its pharmaceutical manufacturing capacity.
Sources:
- Chinese Patent Database: CN102264903, Method for producing a highly active hydroxylated derivative of paclitaxel and intermediate thereof.
- WIPO PatentScope: Patent family analysis for taxane derivatives.
- Scientific Literature: Studies on hydroxylation processes for taxane derivatives, highlighting process improvements.
- Global Patent Records: Examination of international patents related to Paclitaxel synthesis.
